DxS Expand Their Portfolio Of Cancer Mutation Products, With The Launch Of A PI3K Mu

[News]

DxS, a personalised medicine company and market leaders in the provision of companion diagnostics are pleased to announce the addition of a PI3K Mutation Detection Kit to their portfolio of oncogene mutation products. PI3K is a biomarker assessed during the evaluation of the tyrosine kinase inhibitors targeting the EGFR pathway. The PI3K-AKT pathway is activated in a variety of tumour types resulting in cell growth and proliferation.

More... (http://www.medicalnewstoday.com/articles/128790.php)